PerkinElmer acquires Geospiza

PerkinElmer, Inc., a global leader focused on the health and safety of people and the environment, today announced that it has acquired Geospiza, Inc., a leading developer of software systems for the management of genetic analysis and laboratory workflows delivered through a Web-based secure cloud computing environment.

The acquisition of Geospiza supports PerkinElmer's growing offerings in Next Generation DNA Sequencing and Analysis Services, which enable researchers to explore the genomic origins of disease more effectively, and help address customers' growing need to manage knowledge and drive scientific productivity. The addition of Geospiza to PerkinElmer's sequencing and analysis services will deliver an end-to-end solution that provides scientists access to sequencing services and robust analysis and visualization software, offered through significant capability around cloud computing. This solution enables "anytime, anywhere" genomic data interpretation and analysis, all backed by PerkinElmer expertise and the highest quality standards.

"Genomic information is becoming increasingly important in understanding and treating disease. Making sense of the unprecedented volumes of data generated by next generation sequencing and other biological measurements is critical to improve the disease diagnosis process and drug discovery," said Richard Begley, PhD, president, Emerging Technologies, PerkinElmer.

He added, "The acquisition of Geospiza, along with existing software in our various diagnostic businesses, gives PerkinElmer a strong platform for offerings in nucleic acid testing. Geospiza is a leader in its industry, and a strong addition to PerkinElmer's bioinformatics capabilities. We look forward to expanding our family of genetic analysis offerings in research, drug discovery and diagnostics."

Geospiza's clients include biotechnology and pharmaceutical companies, universities, researchers, contract core and diagnostic service laboratories involved in genetic testing and manufacturing biotherapeutics.

Geospiza's current informatics offerings include:

  • GeneSifter™ Analysis Edition - a cloud-based data analysis product for microarray and next generation sequencing data. GeneSifter Analysis Edition helps biologists readily incorporate sophisticated data management and computational analysis into their research efforts. The results include improved quality and productivity in the experimental and decision-making processes. This product is a valuable tool for interpreting the vast amounts of genetic data produced by Microarray and Next Generation Sequencing technologies and supports all of the major sequencing and array platforms.
  • GeneSifter™ Lab Edition - Geospiza's software platform supporting laboratory workflows. This out-of-the-box lab management system with intelligent workflows helps researchers get started immediately, and has flexibility to adapt to specific needs without custom programming. Genesifter Lab Edition significantly increases capacity, reduces backlog, eliminates errors due to manual processes, and speeds time to discovery in user labs.
Source:

PerkinElmer, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    PerkinElmer. (2019, June 19). PerkinElmer acquires Geospiza. News-Medical. Retrieved on October 15, 2019 from https://www.news-medical.net/news/20110506/PerkinElmer-acquires-Geospiza.aspx.

  • MLA

    PerkinElmer. "PerkinElmer acquires Geospiza". News-Medical. 15 October 2019. <https://www.news-medical.net/news/20110506/PerkinElmer-acquires-Geospiza.aspx>.

  • Chicago

    PerkinElmer. "PerkinElmer acquires Geospiza". News-Medical. https://www.news-medical.net/news/20110506/PerkinElmer-acquires-Geospiza.aspx. (accessed October 15, 2019).

  • Harvard

    PerkinElmer. 2019. PerkinElmer acquires Geospiza. News-Medical, viewed 15 October 2019, https://www.news-medical.net/news/20110506/PerkinElmer-acquires-Geospiza.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
An Insider’s Guide to the chemagic™ Prime™ Junior Instrument